

Reviewer #1:

**Scientific Quality:** Grade B (Very good)

**Language Quality:** Grade B (Minor language polishing)

**Conclusion:** Accept (General priority)

**Specific Comments to Authors:** This paper systematically reviews the changes of inflammatory markers in obesity and diabetes. Chronic inflammation and metabolic diseases are considered to be concomitant diseases and are closely related to each other. Therefore, this review has very important clinical value.

We would like to express our gratitude to the reviewer for the very positive feedback on our manuscript. The Minor language polishing mentioned has been taken into consideration and we have checked and revised where any minor errors were observed.

Reviewer #2:

**Scientific Quality:** Grade C (Good)

**Language Quality:** Grade A (Priority publishing)

**Conclusion:** Major revision

**Specific Comments to Authors:** Dear authors, the topic addressed is of great importance for understanding the pathophysiology of obesity, as well as, type 2 diabetes mellitus, and consequently the application of this knowledge in the control/treatment of metabolic diseases. However, reading this manuscript I missed innovation, new mechanisms that can explain the huge inflammation in obesity and how to control. The authors need to add innovative scientific information in order to provide readers with the acquisition of new approaches. Also, is necessary to substitute OBESE in all manuscript to individuals or people with OBESITY. No stigmatization in scientific field. The title could be more attractive. Sugestion: "Physiopathological Mechanisms related to inflammation in obesity and type 2 diabetes mellitus". I suggest to include a new term for NAFLD - that is Metabolic Associated Fatty Liver Disease (MAFLD). Conclusions and future perspectives were shallow, could be more precise.

We would like to thank the reviewer for the overall positive feedback and the specific points mentioned. As reviewer #1 has not asked for corrections but

only for minor language polishing we tried to keep a delicate balance between the two reviewers' suggestions, and we added certain points based on reviewer #2. We have tried to address all the suggestions in the manuscript as follows:

- Regarding the points on innovation, we have expanded the final section regarding obesity and type 2 diabetes mellitus respectively including some newer mendelian randomization studies examining inflammatory biomarkers and BMI related polymorphisms that we found of at most interest.
- We apologise for the use of "obese" on few occasions and now this has been omitted in the manuscript (not possible to change in the already published references) and we have used instead the non-stigmatising terms individuals or people with obesity.
- We agree and we have updated the title as suggested.
- We have omitted the term NAFLD, and we instead included as suggested MAFLD.
- We have expanded and included more precise conclusions and future perspectives in the previously existing conclusion section.